Allogeneic stem cell transplantation remains one of the most powerful tools for preventing relapse in acute myeloid leukemia (AML), but advances in measurable residual disease (MRD) testing, genomic profiling, and targeted therapies are reshaping how clinicians determine who truly benefits from transplant. Rather than a one-size-fits-all approach, transplant decisions are becoming increasingly personalized based on disease biology, treatment response, and individual patient factors.
For decades, allogeneic stem cell transplantation has been considered a cornerstone of post-remission treatment for many patients with AML. The procedure offers the potential for long-term disease control and cure by replacing diseased bone marrow and harnessing the graft-versus-leukemia effect.
Yet transplant is not without risks.
Treatment-related mortality, graft-versus-host disease, infections, and long-term complications remain significant concerns. As AML treatment continues to evolve, clinicians are increasingly asking a critical question:
Does every patient who achieves remission still need a stem cell transplant?
The answer is becoming more complex—and more personalized.
Quick Facts About AML Transplant Decision-Making
-
Allogeneic stem cell transplant remains a standard treatment option for many patients with intermediate- and high-risk AML.
-
MRD status is increasingly used to help determine transplant candidacy.
-
Genomic and molecular profiling are refining risk assessment.
-
Targeted maintenance therapies may reduce relapse risk for some patients.
-
Treatment decisions increasingly balance relapse prevention with quality of life and treatment-related risks.
Why Has Transplant Been So Important in AML?
AML is characterized by a high risk of relapse, even after patients achieve complete remission following induction therapy.
Historically, allogeneic stem cell transplantation has offered the strongest protection against relapse for many patients, particularly those with adverse-risk disease features.
The procedure works through two mechanisms:
-
High-intensity conditioning therapy helps eliminate remaining leukemia cells.
-
Donor immune cells provide an ongoing graft-versus-leukemia effect that can help suppress disease recurrence.
For many years, the decision to proceed with transplant relied heavily on age, performance status, cytogenetic risk, and donor availability.
Today, clinicians have access to significantly more information.
How Is MRD Changing Transplant Decisions?
One of the most important developments in AML management has been the integration of measurable residual disease (MRD) testing.
MRD can identify leukemia cells that remain after treatment at levels undetectable through conventional testing.
Multiple studies have demonstrated that patients who remain MRD positive after treatment face a substantially higher risk of relapse compared with those who achieve MRD negativity.
As a result, MRD status is increasingly influencing post-remission decision-making.
For example:
-
Patients with favorable-risk disease who achieve deep MRD-negative remissions may be able to avoid transplant in certain situations.
-
Patients with persistent MRD may benefit from more aggressive consolidation strategies, including transplant.
-
MRD is increasingly used to refine risk assessment beyond traditional cytogenetic classifications.
Rather than asking whether a patient has achieved remission, clinicians are now asking how deep that remission truly is.
What Role Does Genomic Profiling Play?
Genomic testing has transformed AML risk stratification.
Mutations involving FLT3, NPM1, IDH1, IDH2, TP53, and other molecular markers provide valuable prognostic information that can influence transplant recommendations.
In many cases, genomic findings help identify patients who may be at elevated risk for relapse despite achieving remission.
When combined with MRD data, molecular profiling allows clinicians to develop a more individualized understanding of disease risk.
This shift toward precision medicine is helping move AML treatment beyond broad risk categories and toward more personalized treatment planning.
Could Targeted Therapies Reduce the Need for Transplant?
The growing availability of targeted therapies has introduced another layer of complexity.
Maintenance strategies utilizing FLT3 inhibitors, IDH inhibitors, and other targeted approaches are generating interest as potential tools for reducing relapse risk after remission.
While these therapies are not eliminating the role of transplant, they may influence treatment sequencing and long-term disease management in select patients.
Researchers continue to evaluate whether some patients with favorable disease characteristics and sustained MRD negativity may achieve durable outcomes without immediate transplant.
As these data mature, clinicians may gain greater flexibility when developing individualized treatment plans.
Which Patients Are Most Likely to Benefit From Transplant?
There is no universal answer.
Factors commonly considered include:
-
MRD status following treatment
-
Cytogenetic and molecular risk profile
-
Age and performance status
-
Comorbidities
-
Donor availability
-
Patient preferences and goals of care
For some patients, transplant remains the best opportunity for long-term disease control. For others, the risks may outweigh the potential benefits.
The challenge for clinicians is determining where each patient falls on that spectrum.
What Clinicians Should Know
Stem cell transplantation remains a critical component of AML care, but the decision to proceed with transplant is becoming more nuanced.
Advances in MRD testing, molecular diagnostics, and targeted therapies are helping clinicians personalize treatment recommendations based on each patient's unique disease characteristics and treatment response.
Rather than replacing transplant, these tools are helping identify the patients most likely to benefit while potentially sparing others from unnecessary treatment-related risks.
As evidence continues to evolve, individualized decision-making will remain at the center of post-remission AML management.
Continue the Discussion at LL&M Congress
The evolving role of transplantation in AML will be explored during the session "Post-Remission AML: To Transplant or Not? Navigating Complex Clinical Decisions."
Faculty will examine contemporary risk stratification strategies, the growing role of MRD and genomic profiling, emerging maintenance approaches, and practical considerations for balancing relapse risk against treatment-related morbidity.
Join experts at LL&M Congress to gain practical insights into one of the most important—and increasingly complex—decisions in AML care. Register Now